APP
NKTR icon

Avantax Planning Partners’s Nektar Therapeutics NKTR Stock Holding History

Avantax Planning Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10
Closed -$9K – 879
2018
Q3 		$9K Buy
+10
New +$8.54K ﹤0.01% 914
2018
Q2 		– Sell
-6
Closed -$10K – 1032
2018
Q1 		$10K Buy
+6
New +$7.73K ﹤0.01% 1057

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Avantax Planning Partners's NKTR Position: Q4 2018 in Review

Avantax Planning Partners sold out of Nektar Therapeutics (NKTR) in Q4 2018, closing a stake of 10 shares — an estimated $9K sold.

Avantax Planning Partners first reported a position in NKTR in Q1 2018 and held it in 2 quarters. The position peaked at $10K in Q1 2018. 343 funds tracked by Wall St. Rank hold NKTR as of Q4 2018.

  • Avantax Planning Partners reported no remaining Nektar Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 10 Nektar Therapeutics shares in Q4 2018, an estimated $9K.
  • Avantax Planning Partners first reported a position in Nektar Therapeutics in Q1 2018 and held it in 2 quarters.
  • Avantax Planning Partners's Nektar Therapeutics position peaked at $10K in Q1 2018.
  • 343 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.